Hims & Hers Health Past Earnings Performance
Past criteria checks 4/6
Hims & Hers Health has been growing earnings at an average annual rate of 37.9%, while the Healthcare industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 49.3% per year. Hims & Hers Health's return on equity is 26.4%, and it has net margins of 8.5%.
Key information
37.9%
Earnings growth rate
57.8%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 49.3% |
Return on equity | 26.4% |
Net Margin | 8.5% |
Next Earnings Update | 05 May 2025 |
Recent past performance updates
Recent updates
Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Apr 23With A 29% Price Drop For Hims & Hers Health, Inc. (NYSE:HIMS) You'll Still Get What You Pay For
Mar 24Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Mar 20Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
Mar 03Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity
Feb 25Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Feb 19Hims & Hers Health: Explosive Growth Potential Ahead
Feb 11Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 46% Higher
Feb 04Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Jan 29Hims & Hers Health: The Market Is Likely Wrong
Jan 19Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Jan 09Hims & Hers: Ready For Liftoff In 2025
Jan 02Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted
Dec 19Hims & Hers: Look At What Matters Most
Dec 12Hims & Hers: The Show Must Go On
Dec 05Hims & Hers: Driving Growth In Wellness
Nov 29Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge
Nov 26Hims & Hers Health: The Amazon Curse Is Being Overstated
Nov 15Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Nov 05HIMS: GLP-1 Is Just The Beginning
Oct 17Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Expanding Into Personalized Weight Management And AI Integration Spurs Market Leadership
Sep 05 Expansion into weight management and GLP-1 compounds addresses a massive potential market, suggesting diversification and possible revenue growth.Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Revenue & Expenses Breakdown
How Hims & Hers Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 24 | 1,477 | 126 | 1,028 | 79 |
30 Sep 24 | 1,242 | 101 | 893 | 68 |
30 Jun 24 | 1,067 | 18 | 802 | 60 |
31 Mar 24 | 959 | -2 | 743 | 53 |
31 Dec 23 | 872 | -24 | 693 | 48 |
30 Sep 23 | 793 | -36 | 639 | 43 |
30 Jun 23 | 711 | -47 | 581 | 39 |
31 Mar 23 | 616 | -59 | 514 | 34 |
31 Dec 22 | 527 | -66 | 446 | 29 |
30 Sep 22 | 444 | -86 | 381 | 26 |
30 Jun 22 | 374 | -83 | 324 | 35 |
31 Mar 22 | 321 | -73 | 281 | 28 |
31 Dec 21 | 272 | -108 | 289 | 22 |
30 Sep 21 | 229 | -82 | 250 | 17 |
30 Jun 21 | 196 | -72 | 217 | 0 |
31 Mar 21 | 171 | -63 | 186 | 0 |
31 Dec 20 | 149 | -18 | 113 | 11 |
30 Sep 20 | 132 | -25 | 117 | 0 |
30 Jun 20 | 112 | -38 | 114 | 0 |
31 Mar 20 | 95 | -58 | 117 | 0 |
31 Dec 19 | 83 | -72 | 119 | 0 |
31 Dec 18 | 27 | -75 | 84 | 0 |
Quality Earnings: HIMS has high quality earnings.
Growing Profit Margin: HIMS became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HIMS has become profitable over the past 5 years, growing earnings by 37.9% per year.
Accelerating Growth: HIMS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: HIMS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (16.2%).
Return on Equity
High ROE: HIMS's Return on Equity (26.4%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/04/28 13:47 |
End of Day Share Price | 2025/04/28 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hims & Hers Health, Inc. is covered by 20 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Vikram Kesavabhotla | Baird |
Allen Lutz | BofA Global Research |
Allen Lutz | BofA Global Research |